FDA approves clozapine for treatment of schizophrenia; careful monitoring required.
D000380:Agranulocytosis / Q000139:chemically induced; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D003984:Dibenzazepines; D003024:Clozapine